Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

Major depression is a serious psychiatric disorder and remains a leading cause of disability worldwide.Conventional antidepressants take at least several weeks to achieve a therapeutic response and this lag period has hindered their ability to attain beneficial effects in depressed individuals at high risk of suicide.The non-competitive Nmethyl-D-aspartate glutamate receptor antagonist ketamine has been shown to have rapid antidepressant effects in both rodents and humans.The emergence of ketamine as a fastacting antidepressant provides promising new insights into the development of a rapid treatment response in patients with clinical depression.However,its safety and toxicity remain a concern.In this review,we focus on the limitations of ketamine,including neurotoxicity,cognitive dysfunction,adverse events associated with mental status,psychotomimetic effects,cardiovascular events,and uropathic effects.Studies have shown that its safety and tolerability profiles are generally good at low doses and with short-term treatment in depressed patients.The adverse events associated with ketamine usually occur with very high doses that are administered for prolonged periods of time and can be relieved by cessation.The antidepressant actions of its two enantiomers,S-ketamine(esketamine) and R-ketamine,are also discussed.R-ketamine has greater antidepressant actions than S-ketamine,without ketamine-related sideeffects.Future treatment strategies should consider using Rketamine for the treatment of depressed patients to decrease the risk of adverse events associated with long-term ketamine use.

Abstract Major depression is a serious psychiatric disorder and remains a leading cause of disability worldwide. Con- ventional antidepressants take at least several weeks to achieve a therapeutic response and this lag period has hin- dered their ability to attain beneficial effects in depressed individuals at high risk of suicide. The non-competitive N- methyl-D-aspartate glutamate receptor antagonist ketamine has been shown to have rapid antidepressant effects in both rodents and humans. The emergence of ketamine as a fast- acting antidepressant provides promising new insights into the development of a rapid treatment response in patients with clinical depression. However, its safety and toxicity remain a concem. In this review, we focus on the limitations of ketamine, including neurotoicity, cognitive dysfunction, adverse events associated with mental status, psy- chotomimetic effects, cardiovascular events, and uropathic effects. Studies have shown that its safety and tolerability profiles are generally good at low doses and with short-term treatment in depressed patients. The adverse events associ- ated with ketamine usually occur with very high doses that are administered for prolonged periods of time and can be relieved by cessation. The antidepressant actions of its two enantiomers, S-ketamine （esketamine） and R-ketamine, are also discussed. R-ketamine has greater antidepressantactions than S-ketamine, without ketamine-related side- effects. Future treatment strategies should consider using R- ketamine for the treatment of depressed patients to decrease the risk of adverse events associated with long-term keta- mine use.